Skip Navigation


European Heart Journal Advance Access originally published online on June 22, 2007
European Heart Journal 2007 28(14):1673-1675; doi:10.1093/eurheartj/ehm232
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/14/1673    most recent
ehm232v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cattaneo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cattaneo, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Laboratory detection of ‘aspirin resistance’: what test should we use (if any)?

Marco Cattaneo

Unità di Ematologia e Trombosi, Ospedale San Paolo, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Via di Rudinì 8, Milano 20142, Italy

Corresponding author. Tel: +39 (0) 250323095; fax: +39 (0) 250323095. E-mail address: marco.cattaneo@unimi.it

This editorial refers to ‘A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease’ by M. Lordkipanidzé et al., on page 1702

The first 150 words of the full text of this article appear below.

Aspirin is widely used to decrease the risk of occlusive arterial events in patients at risk. It irreversibly inhibits the cyclooxygenase-1 (COX-1)-dependent synthesis of thromboxane A2 (TxA2), which is essential for the full aggregation response of platelets.

In the last years, the issue of ‘aspirin resistance’ has been emphasized in the medical literature.1–4 Despite several studies published on this subject, its definition, diagnosis, prevalence, causes, and clinical consequences are still uncertain.1

Definition of ‘aspirin resistance’

The term ‘resistance’ to a drug should be used when a drug is unable to hit its pharmacological target, due to inability to reach it (as a consequence of reduced bioavailability, in vivo inactivation, negative interaction with other substances) or to alterations of the target.1 Based on this definition, the term ‘resistance’ to aspirin should be limited to situations in which aspirin is unable to inhibit COX-1-dependent TxA2 production (and, consequently, TxA2-dependent platelet functions).

‘Aspirin resistance’ vs. ‘treatment failure’
If the anti-thrombotic . . . [Full Text of this Article]

‘Aspirin resistance’ vs. ‘high on-treatment residual platelet reactivity’
Methods used to measure platelet function during aspirin treatment

Comparison of different laboratory methods

Anti-platelet treatment: to monitor or not to monitor?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
Marie Lordkipanidzé, Chantal Pharand, Erick Schampaert, Jacques Turgeon, Donald A. Palisaitis, and Jean G. Diodati
EHJ 2007 28: 1702-1708. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
S. Tseeng and R. Arora
Aspirin Resistance: Biological and Clinical Implications
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 5 - 12.
[Abstract] [PDF]